4-28-06

Attorney Docket No. 55600-8014.US02

The



Express Mail Label <u>EV 326 992 505 US</u>

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Liu, et al.

APPLICATION NO.: 10/825,457

FILED: April 14, 2004

FOR: METHOD OF TREATMENT USING

INTERFERON-TAU

EXAMINER: Unassigned

ART UNIT: 1645

CONF. NO: 8343

Supplemental Information Disclosure Statement Within Three Months of Application Filing or Before First Action – 37 C.F.R. § 1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

1. <u>Timing of Submission</u>

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last (37 C.F.R. § 1.97(b)). The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. <u>Cited Information</u>

Copies of references numbered 33, 39, 40, 48, and 53 can be found in parent U.S. Application No. 10/824,710. References numbered 31, 34, 37, 45, 46 and 51 can be found in U.S. parent Application No. 10/884,741. References numbered 30, 32, 35, 36, 38, 41, 42, 47, 50, 52, and 55-56 can be found in U.S. parent Application No. 11/112,369. References numbered 43 and 49 were cited by the Examiner in U.S. parent Application No. 10/824,710.

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5.	<u>Pate</u>	Patent Term Adjustment (37 C.F.R. § 1.704(d))						
		The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpar application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).						
		Respectfully submitted, Perkins Coie LLP						
	.d							

2


Judy M/Mohr

Registration No. 38,563

Correspondence Address:

Date: 4/76/06

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300



				U.S. PATENT DOCUMENTS		
Examiner Initials*	Cite No.		ind Code	Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	H22		Creasey, et al.	02/04/86	
	2	4,683,195		Mullis, et al.	07/28/87	
	3	4,683,202		Mullis	07/28/87	
	4	4,752,479		Briggs, et al.	06/21/88	
	5	4,766,068		Oeda, et al.	08/23/88	
	6	4,769,235		Schlesinger, et al.	09/06/88	
	7	5,098,702		Zimmerman, et al.	03/24/92	
	8	5,128,126		Boniver	07/07/92	
	9	5,368,854		Rennick	11/29/94	
	10	5,376,368		Ulich	12/27/94	
	11	5,425,940		Zimmerman, et al.	06/20/95	
	12	5,563,126		Allen, et al.	10/08/96	
	13	5,632,983		Hadden	05/27/97	
	14	5,880,114		Deluca, <i>et al.</i>	03/09/99	
	15	5,942,223		Bazer, et al.	08/24/99	
	16	6,080,742		Germann, et al.	06/27/00	
	17	6,346,243	B1	Brod	02/12/02	
	18	2003/0017136	A1	Cruz, et al.	01/23/03	
	19	2003/0055013	A1	Brass	03/20/03	
	20	2003/0086901	A1	Cruz, et al.	05/08/03	
	21	6,613,354	B2	Depui, <i>et al.</i>	09/02/03	
	22	2003/0185799	A1	Rudolph	10/02/03	
	23	2003/0229044	A1	Steinman, <i>et al.</i>	12/11/03	
	24	2003/0232033	A1	Cantrell	12/18/03	
	25	2004/0009896	A1	Glynn, et al.	01/15/04	
	26	2004/0013695	A1	Vande-Velde	01/22/04	

EXAMINER		DATE CONSIDERED
*EXAMINER:		nce with MPEP 609. Draw line through citation if not in conformance and not
	considered. Include copy of this form with next communication to a	pplication(s).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Form PTO-1449 (Modified) (Use several sheets if necessary)

of

3

2

Sheet

COMPLETE IF KNOWN				
Application Number	10/825,457			
Confirmation Number	8343			
Filing Date	April 14, 2004			
First Named Inventor	Chih-Ping Liu			
Group Art Unit	1645			
Examiner Name	Unassigned			
Attorney Docket No.	55600-8014.US02			

					U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite	1		d Code	Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages Relevant Figures Appear		
	27	6			Kojima, et al.	03/02/04			
	28	200	4/0086508	A1	Skurkovich, et al.	05/06/04			
	29	2005/0014734		A1	Chang	01/20/05			
				FO	REIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No.	Foreign Patent or Application Kin Office NUMBER (if			of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т	
	30	EP	0 814 831	B1	Soos, et al.	06/19/02		$oldsymbol{oldsymbol{oldsymbol{oldsymbol{\bot}}}$	
	31	EP	1 241 242	A2	Paeschke, <i>et al.</i>	09/18/02			
Examiner Initials*	32 33 34 35	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published. Asadullah, K., et al., Pharmacological Reviews 55(2):241-269, (2003). Chaouat, G., et al., J Immunology 154(9):4261-4268, (1995). Elices, M.J., Current Opinion in Investigational Drugs 4(11):1354-1362, (2003). Fainardi, E., et al., J of Neuroimmunology 142:149-158, (2003).						T	
	36	Goldman, M. and Velu, T., Advances in Nephrology 24:79-90, (1995).							
	37	Groetzner, J., et al., Transplantation <u>77</u> (4):568-574, (2004). Jacobs, R., et al., Rheumatology <u>40</u> :868-875, (2001).							
	38			······································				+	
	39	Kappos, L., et al., J Neurol, <u>251</u> (Suppl 5):V/57-V/64, (2004).							
	40	Killestein, J. and Polman, C.H., Curr Opin Neurol, 18:253-260, (2005).						-	
	41	Kozlowski, L., et al., Annales Acedemiae Medicae Bialostocensis 48:82-84, (2003).							
EXAMINE	₹				DATE CONSIDERED				

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to application(s).

*EXAMINER:

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Form PTO-1449 (Modified) (Use several sheets if necessary)

of

3

3

Sheet

COMPLETE IF KNOWN				
Application Number	10/825,457			
Confirmation Number	8343			
Filing Date	April 14, 2004			
First Named Inventor	Chih-Ping Liu			
Group Art Unit	1645			
Examiner Name	Unassigned			
Attorney Docket No.	55600-8014.US02			

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	Т
	42	Leon, L.R., et al., Annals of the New York Academy of Sciences 856:69-75, (1998).	
	43	Li, M.C and He, S.H., World Journal of Gastroenterology 10(5):620-625, (2004).	
	44	Macdougall, I.C. and Cooper, A.C., Nephrol Dial Transplant 17(Supp 11):39-43, (2002).	
	45	Martin, J., et al., Cytokine 10(8):635-644, (1998).	
	46	Miller, D.H., et al., N Engl J Med <u>348</u> :15-23, (2003).	
	47	Murray, H.W., et al., Infection and Immunity 70(11):6284-6293, (2002).	
	48	Olek, M.J., <i>et al., Neurology</i> <u>56(</u> Suppl 3):A76, (2001).	
	49	van Roon, J., et al., Journal of Rheumatology 30:648-651, abstract only.	
	50	Rennick, D.M. and Fort, M.M., <i>Am J Physiol Gastrointest Liver Physiol</i> <u>278</u> :G829-G833, (2000).	
	51	Sandborn, W.J. and Yednock, T.A., <i>American Journal of Gastroenterology</i> <u>98</u> (11):2372-2382, (2003).	
	52	Soltys, J., et al., The Journal of Immunology <u>168</u> :1903-1910, (2002).	
	53	Tuo, W., et al., J Interferon and Cytokine Research 19(2):179-187, (1999).	
	54	Vanderhoff, B.T., and Tahboub, R.M., Am Fam Physician 66:273-280, (2002).	
	55	Wang, B., et al., J Immunol <u>162</u> :277-283, (1999).	
	56	Waubant, E., et al., J of Neuroimmunology <u>112</u> :139-145, (2001).	

EXAMINER		DATE CONSIDERED		
	· · · · · · · · · · · · · · · · · · ·			
İ	· · · · · · · · · · · · · · · · · · ·	1		
		1		
*EXAMINER:	MINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not			
	considered. Include copy of this form with next communication to application(s).			